Valkyrie Clinical Trials
Los Angeles, CA
Accepting patients
MagnetisMM-32
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab Versus Commonly Used Combination Regimens in Participants with Relapsed/Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Accepting patients
MajesTEC-7
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
- Has results
Accepting patients
TRIlogy-5
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
- Trispecific Antibody
- T Cell Engager (TCE)
- BCMA
- GPRC5D
- Randomization
- Phase 3
Accepting patients
IDP-023
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Natural Killer Cells (Allogeneic)
- Phase 1/2